On August 26, Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267) disclosed its 2025 interim report. As a comprehensive pharmaceutical company with nearly 70 years of experience in the medical industry, the company focused on business growth and efficiency improvement during the reporting period, driving steady improvement in operating performance. The company achieved operating revenue of 5.25 billion yuan, net profit attributable to shareholders of 299 million yuan, and non-recurring net profit of 321 million yuan, representing a year-over-year increase of 23.92%. Cash flow performance was equally robust, with net cash flow from operating activities reaching 1.211 billion yuan in the first half, up 54.98% year-over-year.
Zhejiang Hisun Pharmaceutical stated that in the first half of the year, the company implemented a series of reform measures including structural optimization, system upgrades, business expansion, R&D breakthroughs, management innovation, and brand enhancement, enabling steady progress in operational development and continuous business improvement.
From a business segment perspective, in the first half of 2025, Zhejiang Hisun Pharmaceutical's pharmaceutical formulation sales business maintained steady growth. Products such as Seisumei®, Ximexin®, and Niuzaile® all achieved sales revenue growth exceeding 30% in the first half, effectively driving overall revenue scale improvement in the formulation segment and contributing to profit growth. Among them, Seisumei® (Hibemab tablets), China's first independently developed Class 1.1 innovative drug in the lipid-lowering field and the first domestically developed cholesterol absorption inhibitor, possesses three core advantages: "more effective, safer, and earlier benefits." It has been listed as a Grade A strongly recommended drug in both the "Chinese Guidelines for Lipid Management (2023 Edition)" and "Chinese Guidelines for Lipid Management (2024 Primary Care Edition)." Starting from patients' actual treatment needs, Zhejiang Hisun Pharmaceutical has built a "three-high co-management" chronic disease management model, focusing on the combined management of cardiovascular and metabolic diseases to collaboratively address cardiovascular metabolic disease challenges. With support from Zhejiang Hisun Pharmaceutical, the "2025 Chronic Disease Prevention and Control Quality Science Communication Promotion Action" was jointly launched by the China CDC Chronic Disease Center and People's Health. The company also launched the "Medical Science Video Matrix Project" and the "Haixin Hui" Cardiovascular Ecosystem Alliance, using digital means to reshape user and patient ecosystems and support the implementation of the "Healthy China 2030" strategic goals.
Additionally, Zhejiang Hisun Pharmaceutical continues to develop deeply in multiple disease areas: Ximexin® (adenosyl methionine disulfate tosylate tablets) serves as a first-line treatment for cholestatic liver disease, ranking among the top in domestic market share for similar products; Niuzaile® (omadacycline tosylate tablets) is becoming the new standard for community-acquired infection treatment, working synergistically with a group of high-quality domestic generic drugs to provide complete anti-infection solutions.
While the human pharmaceutical business grew steadily, Zhejiang Hisun Pharmaceutical also demonstrated strong development momentum in the animal health field. The pet medicine business performed brilliantly in the first half, with overall pet business growth exceeding 60%, and pet e-commerce business achieving tax-inclusive sales of over 100 million yuan in six months, with multiple products receiving enthusiastic market response. This year marks the 10th anniversary of "Hailemiao's" launch. Over these ten years, "Hailemiao" became the first domestic deworming drug to achieve sales exceeding 100 million yuan, with cumulative sales surpassing 45 million tablets. Additionally, the dog and cat-specific oral dry suspension antibiotic "Keweishu" successfully launched at the beginning of the year, providing new options for the pet medical market; Zhejiang Hisun Animal Health's first cat triple vaccine product "Haimiaoduo" was launched as a blockbuster product, officially entering the pet vaccine field while expected to promote domestic substitution; "Hailewang" received approval for the Vietnamese market and completed its first shipment, achieving a breakthrough in Southeast Asian market expansion.
The rapid development of these businesses is inseparable from continuous investment in R&D innovation. Zhejiang Hisun Pharmaceutical adopts a combination of "independent research" and "cooperation" to develop innovative drug layouts: its independently developed Class 1 small molecule innovative drug HS387 project received NMPA clinical default approval and officially entered the clinical development stage; the invested Gisen Auma company moved into Zhejiang Hisun Pharmaceutical's Global Marketing Center at the beginning of the year, further deepening cooperation between both parties in the innovative drug field. Zhejiang Hisun Pharmaceutical also reached strategic cooperation with AI drug discovery company Insilico Medicine to conduct artificial intelligence-driven innovative drug R&D cooperation, and focuses on building cutting-edge technology platforms including small nucleic acids, complex formulations, AI R&D, novel small molecules, and synthetic biology, laying the groundwork for continuous launch of future new products.
As one of the key strategic layout directions, synthetic biology also achieved substantial progress in the first half. In June, Yunsheng Synthetic, a Chinese-foreign joint venture wholly-owned subsidiary of Zhejiang Hisun Pharmaceutical focusing on synthetic biology, was officially established, formally entering the high-end synthetic biology industry track. With Yunsheng Synthetic officially commencing operations in mid-August, multiple products are expected to be launched successively within the year, involving fields such as medical aesthetics, orthopedics, and food additives.
While actively expanding into frontier fields, Zhejiang Hisun Pharmaceutical highly values continuous optimization of internal operational efficiency. On the sales side, the formulation segment focuses on refined expense management and improves channel synergy efficiency, achieving continuous improvement in input-output efficiency indicators for sales expenses; on the production side, the company continuously promotes technological innovation and process upgrades, steadily improving production technology levels. Combined with the release of large-scale production effects, production cost reduction work has achieved certain results, with order delivery rates exceeding 99%.
With 2025 already halfway through, looking toward the second half, Zhejiang Hisun Pharmaceutical will continue to uphold its mission of "Sincere Heart, Good Medicine, Achieving Health Dreams," continuously empowering R&D innovation with cutting-edge technologies such as synthetic biology and AI drug discovery, further deepening globalization and innovation-driven strategies, and continuously enhancing long-term value creation capabilities.
Comments